Today we are teaming with the Epilepsy Foundation to release new research coinciding with Purple Day – a global, awareness raising initiative for epilepsy. Already today, the Epilepsy Foundation has raised $100,000 for this worthy cause, and is still counting!
New research released by the Epilepsy Foundation today reveals almost one-in-two Australian adults living with the country’s most common, chronic brain disorder are three-times more likely to experience abnormally high levels of anxiety compared to the general population.[Read more…] about Heightening Epilepsy Awareness on Purple Day
It was a great experience to land in Sydney for the GLOBALHealthPR AGM amidst some of the great healthcare communicators from around the globe. Sitting in the conference room at Park Hyatt Sydney overlooking the Opera House and Harbour Bridge, it was the perfect setting to meet all the partners and discuss global trends in healthcare communication. I did notice that around the world there are newer challenges that the pharmaceutical and healthcare industries are facing as far as effective communication is concerned. As the globe is getting economically stronger and flatter, health issues are dynamically changing. With increasing life spans, the global population is ageing, bringing with it new challenges for elderly care. The fast-increasing incidences of Alzheimer’s, Parkinson’s, cancer and other afflictions are taking a toll on public health and highlight a dire need for early diagnosis and care. [Read more…] about Content, Context and the Future of Health Communication
How appropriate that GLOBALHealthPR Australia partner VIVA! Communications chose Alexion’s David Kwasha to share his personal and Company views on rare diseases on World Rare Disease Day during our two-day annual general meeting in Sydney, Australia last week.
He challenged our group of leading, independent health-focused public relations firms to do more to advance the cause of rare diseases, and in particular, ultra-rare diseases.
In the U.S., a rare disease affects fewer than 200,000 persons, and an ultra-rare disease, fewer than 6,000.
David seemed happy to know that GLOBALHealthPR has already supported the location and identification of nearly 100 percent more children with Progeria, most definitely an ultra-rare disease in which children age rapidly. To date, about 110 children have been identified living with Progeria, an increase from 50 or so just five years ago. We titled our campaign “Find the other 150” because at the time, about 200 Progeria children were estimated worldwide. [Read more…] about Realizing Rare Opportunities
While in Hamburg with our partners at fischerAppelt, I was able to catch a few sessions at Hamburg’s social media week. The most interesting session was focused on the neurobiology of social media, presented by Stefanie Kuhnhen of Grabarz & Partner and Markus von der Lühe of Adknowledge. The presenters conducted focus groups with digital natives (those 13-16 years old) and leveraged neurobiology research to explore why we engage with digital engagement the way we do. [Read more…] about The Future of Social Networking
Here in Sydney, we’ve just concluded our 2014 Annual General Meeting (AGM), the first to be hosted in Australia by our partners at VIVA! Communications. And, we could not be more excited about the outcomes! Early on, we got a heavy dose of local in-country updates from GLOBALHealthPR members, who reflected on accomplishments and challenges alike. Next, we used these responses to inform and refine our strategies moving forward. Our member agencies, from over a dozen countries, also shared the latest healthcare trends in their markets.
GLOBALHealthPR supporting the occasion with denim ribbons
Most importantly, today is World Rare Disease Day and because of this we spent the greater part of the morning discussing the cold hard fact that medical research innovations alone cannot help patients with rare medical conditions. Our keynote speaker, David Kwasha, Managing Director of Alexion Pharmaceuticals, delivered a powerful message and queried why patients should be denied access to treatments for rare diseases. “Why should any human be discriminated against access to life-saving therapy simply because their disease is ultra-rare? Considering the majority of ultra-rare diseases are often the most life-threatening diseases seen in medicine, and commonly affect infants, children and young adults, we need much greater collaboration between government, industry and the general public in this exciting era in which science is unlocking breakthroughs,” said Mr Kwasha. He challenged partners to devise effective communications-driven strategies to address the dilemma of reimbursement for treatments for ultra-rare disease.
Today´s blog post comes to us from Sara Nieto of our GLOBALHealthPR Spain partner, Berbés Asociados.
A client calls his communications partner regarding a new strategic direction that executives have just agreed to take. In the client’s mind, he already has plenty of activities he wants to convey. He provides his press office with new information, data and results to carry out his plan. This new announcement also has significant social importance, so it will interest the general public and is therefore newsworthy. [Read more…] about When Things Work Out Right
Privacy & Cookies
This website uses cookies to ensure you get the best experience on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.